Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Surveillance Imaging Predicts DLBCL Outcomes After AHCT Transplant

Publish date:: February 3, 2020

Key clinical point: Routine PET imaging at day 100 post-AHCT detected asymptomatic relapse.

Major finding: High standardized uptake values (SUVmax) identified patients with a poor expected survival of less than 1 year.

Study details: A single-center retrospective analysis of 131 adult patients to study the impact of day +100 PET/CT on AHCT outcomes.

Disclosures: The study was supported by National Institutes of Health grants. The authors reported no disclosures.

Citation:

Savani M et al. Biol Blood Marrow Transplant 2020. 26:272-77.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,